Dr. Stefanie Grunwald
Dr. Stefanie Grunwald is an expert in intellectual property with a focus advanced therapy medicinal products (ATMPs). With a background in biotechnology and a PhD and postdoctoral training focused on Duchenne muscular dystrophy and myology, she has contributed to translational and experimental research. She combines scientific expertise with a strong foundation in patent law, being qualified through the German Patent Lawyer examination and currently training as a European patent attorney.
Since 2019, she works at the Berlin Institute of Health @ Charité for the evaluation of breakthrough therapies and ATMP-related inventions. Her work aims to develop robust IP protection and to facilitate the translation of research in commercially viable products.
In this session, we start with some key players and emerging trends in the field.
The following topics will be covered:
- IP Protection in Gene and Cell Therapy: basics and scope of industrial IP rights, what is considered confidential, and patents and patentable subject matter. You will learn about what can and cannot be patented, understanding key concepts such as state of the art, novelty, and relevant terminology and related technologies.
- Global Patent Offices and Regulatory Considerations: important jurisdictional differences and legal boundaries.
- Case Studies and Litigation Trends: e.g. CRISPR examples.
Online via MS Teams | Please register HERE!
This lecture series is part of the National Strategy for Gene and Cell-based Therapies.
The organizers reserve the right to change and update the topics and speakers.
All webinars with automatic captioning.
